Tumor Mutational Burden Calculation and Microsatellite Instability Detection in Clinical Next-Generation Sequencing Assays

  • Ashkan Bigdeli
    Correspondence
    Corresponding author.
    Affiliations
    Division of Precision and Computational Diagnostics, Department of Pathology & Laboratory Medicine, Hospital of the University of Pennsylvania, 3020 Market Street, Suite 220, Philadelphia, PA 19104, USA

    Drexel University, School of Biomedical Engineering, Science and Health Systems, 2141 Chestnut Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Amanda Oran
    Affiliations
    Division of Precision and Computational Diagnostics, Department of Pathology & Laboratory Medicine, Hospital of the University of Pennsylvania, 3020 Market Street, Suite 220, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Robyn Sussman
    Affiliations
    Division of Precision and Computational Diagnostics, Department of Pathology & Laboratory Medicine, Hospital of the University of Pennsylvania, 3020 Market Street, Suite 220, Philadelphia, PA 19104, USA
    Search for articles by this author
Published:September 01, 2021DOI:https://doi.org/10.1016/j.yamp.2021.07.008
      TMB and MSI are important biomarkers for use of immune checkpoint blockade therapies in multiple malignancies.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Korman A.J.
        • Peggs K.S.
        • Allison J.P.
        Checkpoint blockade in cancer immunotherapy.
        Adv Immunol. 2006; 90: 297-339
        • Hargadon K.M.
        • Johnson C.E.
        • Williams C.J.
        Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors.
        Int Immunopharmacol. 2018; 62: 29-39
        • Vaddepally R.K.
        • Kharel P.
        • Pandey R.
        • et al.
        Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.
        Cancers (Basel). 2020; 12: 738
        • Goodman A.M.
        • Kato S.
        • Bazhenova L.
        • et al.
        Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.
        Mol Cancer Ther. 2017; 16: 2598-2608
        • Baudrin L.G.
        • Deleuze J.F.
        • How-Kit A.
        Molecular and computational methods for the detection of microsatellite instability in cancer.
        Front Oncol. 2018; 8: 621
        • Nojadeh J.N.
        • Behrouz Sharif S.
        • Sakhinia E.
        Microsatellite instability in colorectal cancer.
        EXCLI J. 2018; 17: 159-168
        • Chang L.
        • Chang M.
        • Chang H.M.
        • et al.
        Microsatellite instability: a predictive biomarker for cancer immunotherapy.
        Appl Immunohistochem Mol Morphol. 2018; 26: e15-e21
        • Chalmers Z.R.
        • Connelly C.F.
        • Fabrizio D.
        • et al.
        Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
        Genome Med. 2017; 9: 34
        • Van der Auwera G.A.
        • Carneiro M.O.
        • Hartl C.
        • et al.
        From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.
        Curr Protoc Bioinformatics. 2013; 43: 11.10.1-11.10.33
      1. DNA-seq analysis pipeline. GDC Docs.
        (Available at:) (Accessed May 6, 2021)
        • Li M.M.
        • Datto M.
        • Duncavage E.J.
        • et al.
        Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
        J Mol Diagn. 2017; 19: 4-23
        • Jennings L.J.
        • Arcila M.E.
        • Corless C.
        • et al.
        Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists.
        J Mol Diagn. 2017; 19: 341-365
        • Ma X.
        • Shao Y.
        • Tian L.
        • et al.
        Analysis of error profiles in deep next-generation sequencing data.
        Genome Biol. 2019; 20: 50
      2. Fda.gov.
        (Available at:) (Accessed May 11, 2021)
        • Kent W.J.
        • Sugnet C.W.
        • Furey T.S.
        • et al.
        The human genome browser at UCSC.
        Genome Res. 2002; 12: 996-1006
        • Umar A.
        • Boland C.R.
        • Terdiman J.P.
        • et al.
        Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability.
        J Natl Cancer Inst. 2004; 96: 261-268
        • Bonneville R.
        • Krook M.A.
        • Chen H.Z.
        • et al.
        Detection of microsatellite instability biomarkers via next-generation sequencing.
        Methods Mol Biol. 2020; 2055: 119-132
        • Niu B.
        • Ye K.
        • Zhang Q.
        • et al.
        MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.
        Bioinformatics. 2014; 30: 1015-1016
        • Chan T.A.
        • Yarchoan M.
        • Jaffee E.
        • et al.
        Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
        Ann Oncol. 2019; 30: 44-56
        • Budczies J.
        • Allgäuer M.
        • Litchfield K.
        • et al.
        Optimizing panel-based tumor mutational burden (TMB) measurement.
        Ann Oncol. 2019; 30: 1496-1506
        • Budczies J.
        • Kazdal D.
        • Allgäuer M.
        • et al.
        Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.
        Lung Cancer. 2020; 142: 114-119
        • Büttner R.
        • Longshore J.W.
        • López-Ríos F.
        • et al.
        Implementing TMB measurement in clinical practice: considerations on assay requirements.
        ESMO Open. 2019; 4: e000442
        • Heydt C.
        • Rehker J.
        • Pappesch R.
        • et al.
        Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
        Sci Rep. 2020; 10: 11387
        • Gallon R.
        • Sheth H.
        • Hayes C.
        • et al.
        Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnostics.
        Hum Mutat. 2020; 41: 332-341
        • Luchini C.
        • Bibeau F.
        • Ligtenberg M.J.L.
        • et al.
        ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
        Ann Oncol. 2019; 30: 1232-1243
        • Sobocińska J.
        • Kolenda T.
        • Teresiak A.
        • et al.
        Diagnostics of mutations in MMR/EPCAM genes and their role in the treatment and care of patients with lynch syndrome.
        Diagnostics (Basel). 2020; 10: 786
        • Hause R.J.
        • Pritchard C.C.
        • Shendure J.
        • et al.
        Classification and characterization of microsatellite instability across 18 cancer types [published correction appears in Nat Med. 2017;23 (10 ):1241] [published correction appears in Nat Med. 2018 Apr 10;24(4):525].
        Nat Med. 2016; 22: 1342-1350
        • Bonneville R.
        • Krook M.A.
        • Kautto E.A.
        • et al.
        Landscape of microsatellite instability across 39 cancer types.
        JCO Precis Oncol. 2017; 2017 (PO.17.00073)
        • Gilson P.
        • Merlin J.L.
        • Harlé A.
        Detection of microsatellite instability: state of the art and future applications in circulating tumour DNA (ctDNA).
        Cancers (Basel). 2021; 13: 1491
        • Wu L.R.
        • Chen S.X.
        • Wu Y.
        • et al.
        Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification [published correction appears in Nat Biomed Eng. 2017 Dec;1(12):1005].
        Nat Biomed Eng. 2017; 1: 714-723
        • Gambin T.
        • Liu Q.
        • Karolak J.A.
        • et al.
        Low-level parental somatic mosaic SNVs in exomes from a large cohort of trios with diverse suspected Mendelian conditions.
        Genet Med. 2020; 22: 1768-1776
        • Strickler J.H.
        • Hanks B.A.
        • Khasraw M.
        Tumor mutational burden as a predictor of immunotherapy response: is more always better?.
        Clin Cancer Res. 2021; 27: 1236-1241
        • Hellmann M.D.
        • Ciuleanu T.E.
        • Pluzanski A.
        • et al.
        Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.
        N Engl J Med. 2018; 378: 2093-2104
        • Marabelle A.
        • Fakih M.
        • Lopez J.
        • et al.
        Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
        Lancet Oncol. 2020; 21: 1353-1365
        • Garofalo A.
        • Sholl L.
        • Reardon B.
        • et al.
        The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
        Genome Med. 2016; 8: 79